Brian Lian - Aug 19, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
President & CEO, Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Aug 19, 2024
Transactions value $
-$6,549,508
Form type
4
Date filed
8/19/2024, 08:13 PM
Previous filing
Jul 31, 2024
Next filing
Aug 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $877K +113K +4.79% $7.77 2.47M Aug 19, 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale -$4.58M -70.1K -2.84% $65.33 2.4M Aug 19, 2024 Direct F1, F2
transaction VKTX Common Stock, par value $0.00001 per share Sale -$2.09M -31.4K -1.31% $66.37 2.37M Aug 19, 2024 Direct F1, F3
transaction VKTX Common Stock, par value $0.00001 per share Sale -$758K -11.3K -0.48% $67.12 2.35M Aug 19, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -113K -32.72% $0.00 232K Aug 19, 2024 Common Stock 113K $7.77 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.90 to $65.8919, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.93 to $66.9091, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.9302 to $67.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 25% of the shares subject to the option vested on each anniversary of the grant date.